Cemiplimab Prolongs Survival in Recurrent Cervical Cancer
Overall survival longer with cemiplimab versus single-agent chemo for recurrent disease after first-line platinum-containing chemo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.